{"title": "âœ… Daily Chat Thread and Discussion âœ…", "selftext": "Please use this thread to discuss what's on your mind, news/rumors on NVIDIA, related industries (but  not limited to) semiconductor, gaming, etc if it's relevant to NVIDIA!", "id": "1fbp4lk", "created_utc": 1725768040.0, "score": 9, "upvote_ratio": 1.0, "num_comments": 26, "comments": [{"body": "Iâ€™m totally a newbie, so please correct me if I say anything wrong. I bought 50 NVDA shares on June 5, 2024, at $122.31 per share and decided to totally forget about them for the next 2 years. Now, three months later, I checked my portfolio out of curiosity and almost had a heart attackâ€¦ Iâ€™m down 17%. I know I have to be patient, and my mindset hasnâ€™t changed - I still want to hold for 2 years - but I was hoping to be at least 1 or 2% in the green. Can someone explain whatâ€™s going on? I live in Europe, so Iâ€™m not really aware of the current situation in America (cus it seems like itâ€™s not just NVDA; all the big tech stocks have almost identical charts).", "score": 4, "replies": [{"body": "The company is still in a good fundamental position if you're a long term investor. There's been some profit taking after the earnings report. Most of my position is in at $115 and I plan to aggressively buy more shares if it falls into the 90s.", "score": 2, "replies": []}]}, {"body": "Thoughts for nvda on Monday am?", "score": 3, "replies": [{"body": "Iâ€™m thinking a drop past 100 along with a general market slide by a few percentâ€”unless there is any major positive news that suddenly comes down the pipes, the trend seems down. \n\nMy wife just cashed out her mutual fund to start direct investing, and despite all the advice to avoid timing the market, I think Iâ€™m just going to sit on it for a couple weeks before plopping it in a broad equity ETF. \n\nMeanwhile, Iâ€™ll be buying converting a few shares of my ETFs into NVDA at each 10 dollars drop.", "score": 3, "replies": [{"body": "Closed at 106.47. Now I delete app and change password. Itâ€™ll see the sun again in due time. Due time", "score": 1, "replies": []}]}, {"body": "Calls!\n\nBut donâ€™t listen to me", "score": 1, "replies": []}]}, {"body": "Damn, PE ratio is in the 40s.  Freaking hilarious that Costco has a PE in the 50s", "score": 3, "replies": []}, {"body": "The NVDA Stochastic momentum index is at the bottoms out max bear. It will swing bull on by Wednesday next week", "score": 2, "replies": []}, {"body": "Feels like a desert in here", "score": 3, "replies": [{"body": "Itâ€™s Sunday", "score": 5, "replies": []}, {"body": "'Bout time.. ðŸ‘", "score": 4, "replies": []}, {"body": "What do you expect?", "score": 2, "replies": []}]}, {"body": "There is Soo much spam in this sub.  Do you guys notice the people posting long posts about a downward economy at 3am?   How is that not a pyschops? So much bullshit", "score": -1, "replies": [{"body": "Don't confuse panic, despair, and fear for a psyop. Occam's razor: the simplest explanation is often the correct one.", "score": 4, "replies": [{"body": "What in the actual f are you talking about?  Are you a bot? I'm in talking about newspaper quality written long posts by \"redditors\". There is no way they are authentic.", "score": -5, "replies": [{"body": "Oh, if that's what you mean... Possibly. There was recently a study that I read that was estimating the percentage of human to AI generated content of the web today and it concluded 57% of the web is now AI generated. I'm not a bot... Although, it would be impossible for you to tell.", "score": 1, "replies": [{"body": "You can trick the bots.  Sunday morning is a great way to see the content I. Talking about, low cost over seas labor is posting it", "score": 0, "replies": [{"body": "Even if it isn't content posted by bots, the troll farms are real and enough to make an impact. I mean before the robot content production army was created, a lot of this was being done by contracting people in less developed nations to produce \"content\" at scale anyways.", "score": 1, "replies": [{"body": "The troll farms, ai or not, are absolutely real and they do have a proven impact or otherwise wouldn't exist. Thought about starting one up myself (to address my long list of grievances lol). But I agree with u/Big_Instruction9922 in that you can often see/smell the troll farm manure.", "score": 3, "replies": [{"body": "It's almost like when I sense too much bs in one direction, ibwantbto go in another. The issue is some are better than others.  Are there any forums with less spam?", "score": 1, "replies": []}]}, {"body": "Yes it's the same difference", "score": 1, "replies": []}]}]}]}]}]}]}]}
{"title": "NVDA's stock dipping could be seen in correlation with the NASDAQ 100 Forward EPS reversing", "selftext": "", "id": "1fc2y8m", "created_utc": 1725815814.0, "score": 19, "upvote_ratio": 0.81, "num_comments": 26, "comments": [{"body": "In other words: big tech in general is very expensive valuation wise. This gets corrected over time because money will eventually move (rotate) to places where more growth is reasonable, sectors which are undervalued. That's how the market corrects itself.", "score": 18, "replies": []}, {"body": "Why don't you explain this to me like I am 10", "score": 11, "replies": [{"body": "Stock market goes up and down. Buy low, sell high.", "score": 16, "replies": []}]}, {"body": "Weeeeeeeeeee!", "score": 4, "replies": []}, {"body": "Everyone has an explanation on whatâ€™s going on. The stock is just going down and consolidating yes. But it does not look like is going to 140 any time soon. Perhaps in October or something. Whoever wants to hold should do it. Me, Iâ€™m out making money with other stocks until the right time comes.", "score": 1, "replies": [{"body": "Tell me you're regarded without telling me. \n\nAnytime soon.. 4 words later, in October.", "score": 17, "replies": []}, {"body": "[deleted]", "score": 11, "replies": [{"body": "Yes. But why hold something thatâ€™s clearly in a down trend ? When I see it going up again Iâ€™ll start my position back. In the meantime my money is making more money in things that are indeed going up", "score": -7, "replies": []}]}, {"body": "Out of curiosity, which other stocks are you making money with right now?", "score": 4, "replies": [{"body": "Heâ€™s not.", "score": 7, "replies": [{"body": "Yes I am. But I wonâ€™t fall for it and tell you which ones. ðŸ¤ ", "score": -8, "replies": [{"body": "Because youâ€™re not.", "score": 9, "replies": [{"body": "Oh but I am ðŸ¤‘", "score": -3, "replies": [{"body": "Iâ€™m making more than you.", "score": 8, "replies": [{"body": "Ok but not in Nvidia", "score": 0, "replies": [{"body": "In Nvidia and any other stock I am making more money than you.", "score": 4, "replies": [{"body": "You donâ€™t even know me wtf is wrong with you are you high ?", "score": 0, "replies": [{"body": "Iâ€™m better than you.", "score": 7, "replies": [{"body": "Username does not check out.", "score": 1, "replies": [{"body": "I praise myself.", "score": 1, "replies": [{"body": "I see. Carry on.", "score": 2, "replies": []}]}]}]}]}]}]}]}]}]}]}]}, {"body": "JNJ for me.", "score": 2, "replies": []}]}]}, {"body": "The stock just split 10 ways after formally splitting 4/1. \nYou canâ€™t use these graphs when that happens. \nThe original stock price for an apple stock today is around $27,000 per share. \nYou arenâ€™t paying $27,000 a share for apple today so historical charting on companies whom have split multiple times at different ratios, makes these charts invalid to determine efficacy.", "score": -1, "replies": [{"body": "You misunderstand the charts", "score": 2, "replies": []}]}]}
{"title": "Lost around 4k in options, never going to check my Nvidia stocks for next 2-3 years ", "selftext": "I put around 100k in Nvidia stock back in Feb/ March for an avg price of $70. Though I made quite a bit of money, I lost ~4k in my sep 20 options for $138c. I thought it will go up after earnings. I decided not to check my robinhood and leave my 1300 shares in my acct for next 2-3 years, the stress that I get out of daily checking due to daily fluctuations is affecting my day to day living. I deserve to live better and not react to these roller coasters. See you all in few years. ", "id": "1fbqwbc", "created_utc": 1725774927.0, "score": 60, "upvote_ratio": 0.89, "num_comments": 30, "comments": [{"body": "Narrator :  the man checked his account 4 days later", "score": 46, "replies": [{"body": "4 hours later..", "score": 10, "replies": [{"body": "Two minutes (best Indian voice).", "score": 6, "replies": []}]}, {"body": "I read this in Morgan Freemanâ€™s voice.", "score": 2, "replies": [{"body": "I read it in the voice of the SpongeBob narrator lol", "score": 2, "replies": []}, {"body": "Samuel L Jackson for me", "score": 1, "replies": [{"body": "Apu.", "score": 2, "replies": []}]}]}, {"body": "more like 4 mins later, shit his pants, sell out all shares", "score": 2, "replies": []}]}, {"body": "Time in as they say is more important than time out. you can't time the market.", "score": 3, "replies": []}, {"body": "If you are selling call options on a stock. then you cannot simply leave the account unsupervised for so long.   \nThere are times when I sell covered calls, and I will buy to close for a 55% profit only a week after selling the calls.   \nYou can then sell them again, repeat...", "score": 6, "replies": []}, {"body": "See you at 6:30 AM", "score": 3, "replies": []}, {"body": "You have a paper gain of $40K and lost $4K on a bad option trade.\n\nI don't think options are for you. \n\nSome people in your position would just sell weekly cover calls on 30% of your position above $70.  Then just collect the premiums.  The only downside is if the stock shoots up way above your strike prices.", "score": 2, "replies": []}, {"body": "Sell some covered calls to make it back", "score": 2, "replies": [{"body": "ez pz xD", "score": 2, "replies": []}]}, {"body": "You shouldâ€™ve taken nvda put bruh. That could give you more money to buy more shares! But now it seems difficult", "score": 2, "replies": []}, {"body": "Donâ€™t buy options on stocks worth more than $100 unless youâ€™re a millionaire. You can easily lose your shirt doing $500 bets a month", "score": 2, "replies": [{"body": "Sounds like you don't know how to predict the market KEKW", "score": 1, "replies": [{"body": "Youâ€™re definitely not a millionaire", "score": 1, "replies": [{"body": "Would that make me right, wrong or hurt my feelings? Are you a millionare? If so, good for you - I hope your mom hugged you enough and you don't hate your life. A random on the internet won't really change my financial journey and I'll be a millionare soon. I'll try to remember and come back to flex because it sounds like fun. Race you to the million, nerd :p", "score": 2, "replies": []}]}]}]}, {"body": "Why? Here's the lesson: Do not play earnings. Simple as that. You can buy the run up a few weeks out, expecting IV to increase and the underlying value to jump on your contracts. You sell the day of or before earnings. After earnings, see what the market is doing. It traded sideways, obviously indecisive so that's a fantastic time NOT to buy. Recognize that NVDA is not out to get you. NVDA does not care about you. NVDA is in fact a stock and does not have any emotions. If you recognize a point where you think it's going to go up, buy a contract a few months out and check the daily chart every few days. \n\nTo your specific point, yes buying and holding and not micromanaging the daily chart is a challenge. One of the harder things in options trading is building and trusting your plan, especially if you dip red the day after. But completely ignoring NVDA is on you, that's a plain money making opportunity when the market decides to get it's head out of it's ass. Practice and discipline with small options contract that won't break your bank until you can trust your swing play - yet have the discipline to be able to look at it and see red in case it's nearing your stops.", "score": 2, "replies": [{"body": "The past couple of earnings seems to indicate the pre earnings peak happens about 2-3 days pre earnings release.", "score": 3, "replies": []}]}, {"body": "What a waste of shares! Why are you not selling CC calls or puts?!? Iâ€™ve been shorting NVDA every week after the split!", "score": 2, "replies": []}, {"body": "see you next week", "score": 1, "replies": []}, {"body": "I can relate. Iâ€™ve backed off from checking mine 20x per day to only 10x.", "score": 1, "replies": []}, {"body": "You and me both. Itâ€™s consumed me. Definitely not healthy.", "score": 1, "replies": []}, {"body": "Good idea, NVIDIA is such a solid long term option.", "score": 1, "replies": []}, {"body": "Sit on what you own and move on.  If it dips and you want to buy more then go for it but you are in it already for 1300 shares so I suggest you diversify and let the 1300 share ride for years.", "score": 1, "replies": []}]}
{"title": "NVDA price scenarios", "selftext": "https://preview.redd.it/vb3n1jcn4nnd1.png?width=453&format=png&auto=webp&s=7826e45deb78a1bf180f98e2488eedfda6d34760\n\nCan someone please check my math and tell me if this looks right?\n\nFrom what I understand, NVDA's average P/E ratio is 50. The past year earnings are $2.10 per share. So the yellow highlighted cell represents a normal current price using that calculation.\n\nLooking forward, a conservative growth rate would give NVDA earnings of $3.04 per share a year from now, so at its typical P/E ratio that would imply a price target of around $150.\n\nAt a more aggressive growth rate - and this is a number Dan Ives threw out - Nvidia might earn $5.00 per share in 2025, which would imply a much higher price per share.\n\nAm I missing anything?", "id": "1fc6na4", "created_utc": 1725825298.0, "score": 15, "upvote_ratio": 0.74, "num_comments": 24, "comments": [{"body": "This is a great table. I think the biggest unknown is if the average P/E for NVDA will hold or will it normalize to other tech giants. High P/E is there because of high growth expectations. It's pricing in future cash flows. But since everyone these days has wildly different opinions on Nvidia's future growth and let's say it does mellow down in line with companies like GOOG, META, AAPL then P/E can fall.\n\nSo can we use the past average P/E as a reliable indicator of future average P/E? That's probably the biggest wildcard in all of this.", "score": 5, "replies": []}, {"body": "NVDA are currently in FY25. Base case is $5.\n\nUsing forward PE is better for a growth company.", "score": 5, "replies": [{"body": "FY 2025 EPS of $5 as base case? That doesn't sound right.", "score": 2, "replies": []}, {"body": "Using forward earnings, the current price should be $150 then?", "score": 2, "replies": []}, {"body": "Is it still considered a growth company?", "score": 0, "replies": [{"body": "Free cash flow in 2024 was +600% from 2023.\n\nWhat on earth do you call that? After decades of cyclicality. They innovated, and this has spurred a new cycle of growth. 2 years ago this company was under $400b. When I started investing in them they were under $100b. \n\nJust because their market cap is where it is, doesn't change that they're a growth company\n\nLink for reference of business growth\n\n[https://www.dsaprospect.co.uk/hs-fs/hubfs/Blog%20Images/DSA%20Prospect%20The%20Business%20Lifecycle%20Chart.png?width=600&height=450&name=DSA%20Prospect%20The%20Business%20Lifecycle%20Chart.png](https://www.dsaprospect.co.uk/hs-fs/hubfs/Blog%20Images/DSA%20Prospect%20The%20Business%20Lifecycle%20Chart.png?width=600&height=450&name=DSA%20Prospect%20The%20Business%20Lifecycle%20Chart.png)", "score": 6, "replies": []}]}]}, {"body": "Price range is $60 - $150 in the next year. \nTell yourself how youâ€™ll react in both scenarios because nobody knows which it will be. \n\nItâ€™s possible you see it go down to $80 in the next few months and hover there for a while. What would you do to make yourself feel comfortable. \n\nBuy more? Average down. Knowing it could go to $60. Maybe then buy even more. And wait for it to go back up to $120.\n\nEdit; the numbers above were off top of head before looking at your chart. Ended up pretty much exactly with your analysis. Iâ€™d say 30-40 P/E ratios are the right ones to anchor on", "score": 3, "replies": []}, {"body": "might go up might go down", "score": 5, "replies": [{"body": "Well said, and I agree", "score": 3, "replies": []}, {"body": "It could go sideways too", "score": 0, "replies": []}]}, {"body": "How do you know the market will price Nvidia at 50 pe, which is a 2% yield essentially. Letâ€™s say they earn $3 eps but the market becomes bearish and prices at 25 pe, then the share price would be $75, which is lower than what it is right now. \n\nAlso, how are you so certain it will earn $3 eps? At $3eps, you are predicting the company will earn $75Billion net income.", "score": 2, "replies": [{"body": "I donâ€™t know what the future p/e will be - that a why I gave a range- but historically it has averaged 50. \n\nI also donâ€™t know what their next year eps will be but the most recent quarter was 67c. With zero growth that implies an eps of $2.68. So even with minimal growth they will easily achieve $3. \n\nFor me the big question is how much Blackwell will boost earnings.", "score": 3, "replies": [{"body": "I'm so confident in Blackwell boosting earnings that I will sell my entire position if it barely moves by 2026. Blackwell isn't factored into anything right now and its demand is exceeding production with chips that will set a new benchmark for the entire AI industry.", "score": 3, "replies": []}]}, {"body": "FY25 is going to come in at minimum $100b.", "score": 2, "replies": [{"body": "Please come back to this post end of next year to check back on your prediction!", "score": 2, "replies": []}]}, {"body": "50x is their average P/E over the past ten years (actually itâ€™s 49.8)", "score": 2, "replies": [{"body": "Just because itâ€™s been 50 pe for the last 10 years doesnâ€™t mean it will trade at 50 pe for the next 10 years. 50 pe in general is an extremely high multiple.", "score": 2, "replies": [{"body": "Hereâ€™s the past ten years: \nHereâ€™s a breakdown of **Nvidiaâ€™s P/E ratio** over the past 10 years based on available data:\n\n1. **2024**: Around 48-76x, fluctuating with the stockâ€™s rapid growth and earnings adjustments [oai_citation:7,NVIDIA Corporation (NVDA) Statistics & Valuation Metrics - Stock Analysis](https://stockanalysis.com/stocks/nvda/statistics/) [oai_citation:6,NVIDIA (NVDA) PE Ratio Chart - NVDA Stock Price to Earnings Ratio History](https://www.financecharts.com/stocks/NVDA/value/pe-ratio).\n2. **2023**: Between 40x and 160x, reflecting volatility tied to the broader AI boom and Nvidiaâ€™s strong earnings performance [oai_citation:5,NVIDIA Corporation (NVDA) Statistics & Valuation Metrics - Stock Analysis](https://stockanalysis.com/stocks/nvda/statistics/).\n3. **2022**: Averaged about 41x-55x, with a high driven by Nvidiaâ€™s expansion in AI and data centers [oai_citation:4,NVIDIA (NVDA) PE Ratio Chart - NVDA Stock Price to Earnings Ratio History](https://www.financecharts.com/stocks/NVDA/value/pe-ratio).\n4. **2021**: Peaked around 90x due to strong earnings growth, particularly from gaming and data center segments [oai_citation:3,NVIDIA (NVDA) PE Ratio Chart - NVDA Stock Price to Earnings Ratio History](https://www.financecharts.com/stocks/NVDA/value/pe-ratio).\n5. **2020**: Around 50x, supported by a surge in demand for Nvidiaâ€™s GPUs and AI hardware.\n6. **2019**: Roughly 31x, reflecting a period of strong recovery after a market downturn in late 2018.\n7. **2018**: Peaked at around 40x before the market experienced some corrections.\n8. **2017**: Reached about 50x as Nvidiaâ€™s stock gained momentum from its leadership in AI and GPU technology.\n9. **2016**: Averaged 33x, boosted by growth in gaming and data centers.\n10. **2015**: Around 18x, as Nvidia was still primarily seen as a gaming hardware company, before its expansion into AI and data centers took off [oai_citation:2,NVIDIA (NVDA) PE Ratio Chart - NVDA Stock Price to Earnings Ratio History](https://www.financecharts.com/stocks/NVDA/value/pe-ratio) [oai_citation:1,NVDA (NVIDIA)  PE Ratio](https://www.gurufocus.com/term/pe-ratio/NVDA).\n\nThese figures show how Nvidiaâ€™s valuation has evolved dramatically in response to market shifts, driven primarily by its leadership in AI, gaming, and data center technology.", "score": 3, "replies": [{"body": "Doesnâ€™t mean it will stay pe of 50 in perpetuity.", "score": 1, "replies": []}]}, {"body": "By the way, AMDâ€™s P/E is 160+", "score": 1, "replies": [{"body": "In other words, if everything stays the same it will take 160 years to get your money back. Very smart roi in my opinion!", "score": 1, "replies": []}]}]}]}]}]}
{"title": "The Second Leg Down and crisis alpha capture in a recession", "selftext": "Has anyone read The Second Leg Down by Krishnan? Subtitle \"strategies from profiting after a market sell-off\" describes it pretty well, though it is more a mix of technical and shop-talk for fund managers than a cookbook for investors.\n\nThe biggest takeaway for me was the idea of using short 1x2 put ratios as a cost effective hedge. Is this really a good idea in practice?\n\nCan anyone advise any better strategies for profiting from a recession and big market drop this fall, if it happens?\n\nEdit: Let me expand a bit on what Krishnan is recommending as it might be useful for others if they are interested. The context of the hedge is a major crash/recession, not a downward swing or correction (the image below should explain why). He's suggesting rolling the short 1x2 put ratio where a 25 delta is bought, and two 10 delta are sold. He goes into detail on why he feels that these deltas are under and over priced respectively (book is from 2017, not sure if his assumption holds for all symbols or even fully today).\n\nhttps://preview.redd.it/v94793x0whnd1.png?width=471&format=png&auto=webp&s=975f4b9578d4d4c2d458b1dd44a50576e29e673e", "id": "1fbmtai", "created_utc": 1725759933.0, "score": 16, "upvote_ratio": 0.76, "num_comments": 19, "comments": [{"body": "If the market is not dropping fast youâ€™re in trouble as you might expire in between strikes: https://youtu.be/ypdIQ4Kuxfo?si=2BjYFPNDnbAmMZOE", "score": 9, "replies": [{"body": "Yeah good point. I failed to mention that Krishnan is talking about the short 1x2 put ratio as a rolled position rather than holding to expiration. BUT still, the DTE of the options and how they are rolled could make a huge difference -- worst case basically following the market down.", "score": 2, "replies": [{"body": "Agree, rolling it would just take the loss and opening a new one during vol expansion where youâ€™ll have an even bigger strike between the longs and the short put because of the skewness expanding", "score": 2, "replies": []}]}]}, {"body": "I had some beginners' luck. Covid had me nervious in Feb 2020. I had read Mark Spitznagel but didn't know how he hedged. I stumbled onto the backspread just in time to try my first one.\n\nI put on a 1:2.5 backspread on Feb 18th with VIX at 12ish at a cost of $700. The next two days the SPX would rise 10pts and that would be the top. The long strike was 2400, 30% below market.\n\nSold on Mar 16th for $66,000 with VIX at 80ish when SPX touched my long strike the second time, just 3 days before the lowest and last low.\n\nThe dissonance was horrible! Rooting for the tail hedge while your stocks are tanking! I closed when the SPX was centered in the valley of death, but because of increased vol, the whole P/L graph was lifted up, a lot!\n\nUnfortunately, when this happens to you, on your first attempt, no less, you become a believer. Spent the next 12mos doing an always-on tailhedge. My cost came out to 2% of the capital that was dollar-for-dollar insured. Too back graphics can't be posted here on r/etfs. I kept a spreadsheet of all my trades.", "score": 7, "replies": [{"body": "Very interesting! I've intrigued by using on the VIX too...I guess calling the top isn't very important then (entry that is, exit clearly still matters...)? Clever solution, I'm going to have to consider that.\n\nI'm also curious about using OptionAlpha to automate the tailhedge rolling.\n\n\"Mark Spitznagel but didn't know how he hedged\" lol tell me about it. Spitznagel is very coy about how he hedges, as is Taleb (at least nothing I've read from either is very clear on it). That's given me some skepticism as to what cards Krishnan might not be showing -- part of my reason for asking here on Reddit.", "score": 1, "replies": [{"body": "[deleted]", "score": 3, "replies": [{"body": "Professional traders back by massive amounts of capital struggle to play the VIX properly, please be careful here people.", "score": 2, "replies": []}]}, {"body": "Wasn't it in Second Leg Down where they talk about how to be long the (imperfect) VIX in the most efficient way? Maybe it was a different book. I seem to remember that the best outcome comes from being long VXX calls and short VIX futures. (But with a gotcha being that both parts of the trade would have to be in different accounts which increases margin requirements a lot)", "score": 2, "replies": [{"body": "Paging through the book at the moment...I'm not finding that spot. He does talk about VIX futures and VXX several places though. Maybe I'm not making the connection.", "score": 1, "replies": [{"body": "I've got the Kindle version. It's in chapter Migrating to VIX Options on pg 101.", "score": 2, "replies": []}]}]}]}]}, {"body": "Good book.  I remember something about using different hedges (i.e. single puts, trend following down, ratio spreads) for different market conditions (i.e. first leg down, second leg down, severe trend down).    I think 25 delta short leg was always best for most overpriced theta and gamma.", "score": 3, "replies": [{"body": "Any similar books you'd recommend? I've read (most) of his other book \"Market Tremors\"...interesting but not something I really have been in any position to apply practically.", "score": 1, "replies": [{"body": "Iâ€™m not familiar with any of his other books.   Iâ€™m pretty sure there is YouTube presentation by him about this book.", "score": 2, "replies": []}]}]}, {"body": "The 2x1 is ok but timing is everything so it's easy to mess up, I think mindlessly putting it on is expensive\n\nI think the concept of clustering was more important to know", "score": 3, "replies": [{"body": "Hi, can you kindly explain clustering in this context?", "score": 2, "replies": [{"body": "Big moves give rise to big moves, the best time to hedge is before the first big move, the second best time is after the first big move (hence the name of the book) even though puts will be expensive", "score": 3, "replies": []}]}]}, {"body": "It's a great idea when it works.  Otherwise, not so much..\n\nAs evident from your graph, the risk is the area between the strikes, where you can lose money on both legs.\n\nThe short leg is subject to early assignment, so you have to actively roll it when time premium fades.\n\nWhen I've used these, I try for delta neutral and for no cost or a credit. In addition, I prefer to diagonalize them so that it's possible that I may end up owning the long legs for free or at a reduced cost.  That saved me in 2020 when Covid hit because I had leftover near worthless long puts about to expire and I sold them for $15 to $22 each.", "score": 2, "replies": []}, {"body": "What about layering an iron condor (since vol is high) to help \"pay\" for this second-leg down hedge, or the risk of the market going sideways. This alleviates the pressure of always finding the self-funded hedge in a single trade?", "score": 1, "replies": [{"body": "Or \"just\" an IC with very wide wings in the first place? Let time work for you.", "score": 2, "replies": [{"body": "Right.. the wings should be crazy wide, like in March 2020, but the market bounced back quick, so you'd still need to close that trade before expiry from a risk management pov.", "score": 1, "replies": []}]}]}]}
{"title": "NVDA Dip - What the heck was that? Did any of you manage to get orders filled sub-$60?", "selftext": "", "id": "1fbteze", "created_utc": 1725785754.0, "score": 0, "upvote_ratio": 0.16, "num_comments": 29, "comments": [{"body": "I swear before I die, i'll see a day on this sub without this dumb question ask everytime google fuck up the chart. But not today apparently...", "score": 131, "replies": [{"body": "Exactly. Or people using yahoo financeâ€¦ just use TradingView for live data ffs.", "score": 12, "replies": []}, {"body": "Flash crashes do happen.", "score": -85, "replies": [{"body": "Well check any other source, maybe a serious one, not fucking google chart to see that it did not happen. \nIf it had happened, this sub and others would have lost their mind and there will already be 200 post talking about it", "score": 27, "replies": []}, {"body": "Flash billionaires donâ€™t happen though", "score": 5, "replies": []}, {"body": "Cool, show us some recent examples of that happening", "score": 1, "replies": []}, {"body": "You definitely wouldn't be the only person posting about it on a Sunday if it happened on Friday tho", "score": 1, "replies": []}]}]}, {"body": "Yes my short position made me a millionaire and my calls which I bought in the same millisecond of the crash made me a billionaire", "score": 40, "replies": [{"body": "*Dial on the phone*   Hello is this Mister Nasdaq ?! This Is anon. I would like to know why my nvda buy order of 100k shares at 60$ didn't trigger when the google chart says it did reach 57$ after hours ?! I'm now asking for compensation for 4 million dollar because google chart clearly show it did go to 57$ !", "score": 20, "replies": [{"body": "ðŸ˜‚ðŸ˜‚ðŸ˜‚", "score": 1, "replies": []}]}, {"body": "I bought 10,000 shares of Berkshire A when it dropped 99.99% a couple months ago. Iâ€™m happy with the discount but thereâ€™s not enough currency existing in the world yet to sell them.", "score": 5, "replies": [{"body": "I would like to see a screen shot of that buy order, I thought all orders got cancelled because no broker in their right mind would fill that..?", "score": 0, "replies": [{"body": "no, it's 100% true. i bought out warren buffett. he had to sell his apple shares to buy back berkshire from me.", "score": 3, "replies": [{"body": "Solid story-SOLD.", "score": 1, "replies": []}]}]}]}]}, {"body": "Glitch better have my money", "score": 9, "replies": []}, {"body": "probably a glitch", "score": 8, "replies": [{"body": "Just like chase bank?   Lol", "score": 2, "replies": []}]}, {"body": "Another day where this type of screenshot gets posted for the 1000th time.", "score": 7, "replies": []}, {"body": "Would be nice to go one day without someone posting this exact same thing.", "score": 6, "replies": []}, {"body": "It is so embarrassing that this gets posted everyday like holy shit", "score": 2, "replies": []}, {"body": "Yeah Iâ€™m rich from NVDA alone.", "score": 2, "replies": []}, {"body": "Iâ€™m pretty sure itâ€™s from call options being assigned. Right before the close you could have paid around $42.83/share to buy the right to buy shares for $60/share. No one submitted a market sell order so if your limit buy orders wouldnâ€™t be triggered.", "score": 2, "replies": []}, {"body": "Usually when this happens it's someone exercising their call options.", "score": 4, "replies": [{"body": "Is it possible if you had a limit buy set up at $60 they would have gotten filled?", "score": -6, "replies": [{"body": "No. The price didn't actually go there. It's just someone picking up their shares.", "score": 3, "replies": []}]}]}, {"body": "Looks like a fat finger trade or high vol of trades processed down at market rate (not limit) to move into cash before the weekend to minimize risk.", "score": 1, "replies": []}, {"body": "Every single day, sighâ€¦.", "score": 1, "replies": []}]}
{"title": "The complexity of Bio stock. $IBRX  ImmunityBio, a long hard (expensive road) for Anktiva.  ", "selftext": "Edit for the traders \n\nShort interest 29%,  49 million shares, 18 days to cover.  For traders, this is  set-up equals a perfect storm.\n\n==========================================================\n\nEDIT TODAY 9-9-2024\n\n# ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVAÂ® and Checkpoint Immunotherapy at World Conference on Lung Cancer\n\n* Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2^(nd)Â and 3^(rd)Â line NSCLC cancer patients who progressed on checkpoint inhibitors such as KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab)\n* ANKTIVA plus KEYTRUDA or OPDIVO rescued T cell activity in these patients who progressed on the same checkpoint inhibitor with overall survival of 57% at 12 months\n* Long-term survival was independent of PDL1 tumor status and independent of 2^(nd)Â or 3^(rd)Â line of therapy\n* The data continues to validate the mechanism of action ofÂ ANKTIVAÂ in activating NK, CD8 killer,Â and Memory T cells resulting in prolonged overall survival in patients with advanced cancers\n* Data supports global launch of Phase 3 randomized control of ResQ trials of ANKTIVA plus KEYTRUDA or OPDIVO in 1^(st)Â and 2^(nd)Â line NSCLC (ResQ301 and ResQ302) versus standard of care\n\n=======================================================================\n\n8/9/2024\n\nBio Investments can be extremely risky.  Once in a while we see a unique company pursuing unique science with massive potential.\n\n* **Immunity Bio's Anktiva a new blockbuster**\n   * ANKTIVA, developed by ImmunityBio, has received FDA approval for use in combination with BCG (Bacillus Calmette-GuÃ©rin) to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This drug leverages the immune system, particularly by stimulating natural killer (NK) cells and T cells, to fight cancer, offering a promising new treatment option for patients who previously faced invasive surgery\n   * ANKTIVA is also being investigated for multiple other conditions, including various solid tumors, non-Hodgkin's lymphoma, non-small-cell lung cancer, and HIV\n* **Immunity Bio Finances at a glance**\n   * ImmunityBio is experiencing deficit and cash-flow challenges, according to the filing. As of June 30, the company had an accumulated deficit of $3.2 billion. It also had negative cash flows of $207.3 million during the six months ended June 30.\n   * The company also said in the filing that it believes there is substantial doubt about its ability to continue without additional funding. However, it went on to note that its existing cash, cash equivalents and investments in marketable securities; sales of approved product; capital to be raised through equity offerings; and potential ability to borrow from affiliated entities will fund operations through at least 12 months.\n* **Understanding the CEO**\n   * Soon-Shiong's net worth isÂ **$6.2 billion**Â as of 2024. He has been called the richest man in Los Angeles and one of the wealthiest doctors in the world.\n   * Soon-Shiong purchased Fujisawa, which sold injectable generic drugs, in 1998. He used its revenues to developÂ Abraxane, which took an existing chemotherapy drug,Â Taxol, and wrapped it in protein that made it easier to deliver to tumors. He was able to quickly move it through the regulatory process and made his fortune with this medicine\n      * [https://en.wikipedia.org/wiki/Patrick\\_Soon-Shiong#References](https://en.wikipedia.org/wiki/Patrick_Soon-Shiong#References)\n* **ImmunityBio  Strategic partnership in India.**\n   * Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVAÂ®, ImmunityBioâ€™s recently approved treatment for non-muscle invasive bladder cancer (NMIBC)\n   * Serum Institute of India (SII) will manufacture both standard BCG (â€œsBCGâ€) and next-generation recombinant BCG (â€œiBCGâ€), creating a long-term solution to chronic BCG supply shortage issues\n* **Next indication approval**\n   * ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer\n      * QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2^(nd)â€“ and 3^(rd)-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy.\n      * Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC\n      * Data reaffirmsÂ the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types\n* **Presentation TODAY (08/09/2024)**\n   * **Results**: The median OS (n=86) was 14.1 months (95% CI 11.7, 17.4) with 24 ongoing survival to date. In 3^(rd)Â line+ve (n=25) median OS was 14.8 months (95% CI 9.1, 26.7). OS for PDL1+ve (>1%) (N=53) was 13.8 months (95% CI 10.2, 17.4) versus PDL1-ve (N=33) blah blah blah......... [https://cattendee.abstractsonline.com/meeting/20598/Session/142Conclusions:](https://cattendee.abstractsonline.com/meeting/20598/Session/142Conclusions:) Anktiva plus CPI therapy in 2ndÂ line or greater NSCLC demonstrated long-term median OS, independent of PDL1 status, and independent of prior lines of therapy in patients with acquired resistance to CPI. These findings support the novel mechanism of action of Anktiva to rescue CPI activity through the activation of NK and T cells, driving long-term memory, with median OS ongoing survival of 33% and 30% at 18 and 21 months respectively, exceeding the standard of care.\n* **Conclusion (or my opinion)**\n   * IBRX has in Dr. Soon  a business man that knows how to invest and get returns. It is likely IBRX will have all rights to USA/North America - but  will partner with Big Pharma (J&J, Astra or so) for EMEA region.  Looking at his previous businesses,  I assume he will do the same once again.  Sell/partner at the right moment.  Estimated sales is 900 million p/a by 2028.  That is for 1 indication only.\n   * A partnership will likely alter the balance sheet of IBRX, see an upfront payment and milestone payments too.\n      * Part of my thesis is UK approval.   While Europe approvals take time, UK approval is easier. due to the International Reliance Procedure \\[7\\]. If the MHRA decides to take this road for approving Anktiva, then (at least theoretically) a UK approval could be a fact within 2024............ **And guess where the plane of the Dr. has been this month?  Yes, Heathrow.**", "id": "1fbyq9a", "created_utc": 1725804791.0, "score": 11, "upvote_ratio": 0.71, "num_comments": 34, "comments": [{"body": "u/Bossie81\n\nI have a few questions:\n\n1. How is it that IBRX's accumulated deficit of $3.2 billion is more than half of Soon-Shiong's net worth, if he didn't deliberately saddle it with debt (I'm not saying he did; I'm just asking)?\n2. If IBRX only has enough cash and cash equivalents to fund operations through at least 12 months, doesn't that mean a share dilution is very likely in the near future? Wouldn't IBRX be \"cutting things a bit close\" if they don't do it within the next 3 months?\n3. The stock price is lower today than it was when the FDA approval was given. What does this mean for sales? Does it - for example - mean that other drugs are being preferred, over Anktiva? Does it mean that Anktiva's efficacy has been exaggerated, since it's not effective on its own but has to be taken alongside BCG?\n4. Which other drugs are competing with Anktiva in the treatment of NMIBC, and how do their sales compare with those of Anktiva?\n5. Are there any official dates or timelines by which UK approval is expected?\n6. You say his plane has been at Heathrow Airport for this month. Is it likely that he is pushing for UK approval, so he can then announce some shares dilution?", "score": 7, "replies": [{"body": "Hi.\n\n1. Delays in approval play a part.  Complete response letter FDA.  Further, the enormous sales team comes with a huge price tag.  Trials are extremely expensive,  I believe 505k - 150k per participant., depending on the type of drug/treatment.\n2. Yes. Share dilution is possible.  However, it is my opinion the will partner to create liquidity. Soon owns 80% of the stock,  so he has in interest too.\n3. Look at Akebia, Iovance,  Coherus, Xfor and others that had PDUFA/approval.  Approval means nothing,  IBRX was in the luxury position of being able to ship 2 weeks after approval. Unique. However, the market still needs to be informed, trained, insurance deals covered.  An approval, as with the given examples,  are in indication of future value. Especially when it does not concern Big Pharma.\n4. Keytruda and Opdivo (I believe).  If you look at Opdivo   wiki, you can see a approval path - I think  Anktiva has the same timeline.\n5. UK is my guess. Not fact.  It is simply logic.  The fastest to obtain.\n6. UK approval, in my opinion,  will go with a partnership.  I do not see how they can not. If they do not partner,  they will need to dilute. With Bio stock anything is possible.  You have to be willing to see red.  A partner can bee in many forms, but if this occurs there will be a big investment (my guess 500,000,000 minimum) and hefty milestone payments for each indication.", "score": 5, "replies": [{"body": "If you don't mind, you didn't quite answer Question 5, re whether there are any official dates or timelines by which UK approval is expected.", "score": 1, "replies": [{"body": "European Regulatory Filing\nImmunityBio has begun the filing process for obtaining regulatory approval for ANKTIVA in the European Union (EU) and United Kingdom. The filing will include 30 countries, including 27 in the EU and three in the European Economic Area. The company anticipates completing the submission of the initial EMA filing in Q4 2024. (Communicated in August)\n\nUK will likely  be first. Q4 or Q1 a reasonable assumption.", "score": 3, "replies": [{"body": "Noted. Thanks.", "score": 1, "replies": [{"body": "Welcome Sir.  \n\nIt is evident the current situation is not ideal. If an ATM was applied, it would have been done already. If dilution would take place,  I am guessing a direct placement. Oberman also has a massive interest (200 million and I am sure there are some negatives to be found in sec filing).  \n\nI do however believe, based on Soon his business record, he knows how to drive value, and chose the opportune moment to act.   Note the strategic move to use India to resolve a global shortage.  This nugget is glanced over easily. \n\nAlso, he clearly is  a philanthropist,  his age 73 (or so),  I think this is his legacy - no way no how he is going to let that go bankrupt or be spoiled by monetary issues.", "score": 3, "replies": [{"body": "Yes, I read about the India move some months ago. It seems like it's a very wise move on the part of Soon, since Anktiva is so dependent on a regular supply of BCG.   \n  \nHe sounds like an incredible visionary; let's hope that it translates into full approval and usage of Anktiva, and a nice appreciation in the stock price.", "score": 1, "replies": [{"body": "To be honest,  I am waiting for the price to drop.  I WANT it to drop.  lower 2 area. Yes, that will see me 50% down.  I do not care. \n\nI am Dutch, I am cheap, I want these shares cheap.  To average 3$ in the end,  I believe would be excellent.", "score": 2, "replies": [{"body": "LOL!!!! Since it's almost inevitable that this stock will shoot up one day, I understand what you mean, and I can see the appeal of getting it even cheaper than it is now.", "score": 1, "replies": []}]}, {"body": "Here you go, as I suspected.\n\nFresh off the press\n\n[https://finance.yahoo.com/news/immunitybio-presents-positive-long-term-123000487.html](https://finance.yahoo.com/news/immunitybio-presents-positive-long-term-123000487.html)", "score": 1, "replies": [{"body": " u/Bossie81 Wow! Very promising information. So, based on this news, ImmunityBio are opening fresh trials for Anktiva on NSCLC, they're not going for FDA approval or European approval for it, as it's too early for that. This isgood news, though it will probably not move the share price much, until these fresh trials are either completed or have progressed enough to produce really good and tangible results. IBRX is up 4% today (it was 9.2% at one point); let's see whether the stock price increase holds. \n\nAll in all, it's good for the ImmunityBio to have something else in the pipeline, as well as the approval for NMIBC that they're trying to get in Europe.", "score": 1, "replies": [{"body": "Look at the Opdivo wiki, it sketches a timeline for indication approval.\n\nImmunity, as I see it, has only ONE job.  Address the financial issue. Show the world a partner. They do that (for instance Bristol Meyer Squib),  this stock will run to 15$ - 30$ range.\n\nHere lies the danger for the retail investor too.  Dilute more.  There is always that possibility.", "score": 3, "replies": []}, {"body": "[https://journey.ct.events/view/34424413-51f2-47f0-9757-e2dec9f93284](https://journey.ct.events/view/34424413-51f2-47f0-9757-e2dec9f93284)", "score": 1, "replies": []}]}]}]}]}]}]}]}]}]}, {"body": "Great DD, thanks", "score": 3, "replies": [{"body": "[https://finance.yahoo.com/news/immunitybio-presents-positive-long-term-123000487.html](https://finance.yahoo.com/news/immunitybio-presents-positive-long-term-123000487.html)", "score": 1, "replies": []}]}, {"body": "I invested at.6.380 and have been following it ever since. My suspicion is that this company will go bust.", "score": 1, "replies": [{"body": "Why do you think it will go bust, since the founder is very wealthy, and since the drug has received FDA approval for NMIBC?", "score": 3, "replies": []}, {"body": "As per conference call - they stated they had various offers 'as how to help'.  That translates to:  BP is pulling.\n\nMerck,  Bayer, Pfizer, many BP need a win. Anktiva is that win.", "score": 3, "replies": [{"body": "\"BP is pulling\"? Sorry, who or what is \"BP\" and what are they pulling? I keep thinking \"British Petroleum\" but surely it can't be that.", "score": 3, "replies": [{"body": "Big Pharma", "score": 2, "replies": [{"body": "I see. Thanks for that.   \nA couple of questions:   \n  \n1) Since the companies you mentioned - Merck, Bayer, Pfizer - are all very established, surely Anktiva isn't going to dramatically affect their revenue, or is it?   \n  \n2) If Anktiva isn't the only drug under consideration for NMIBC - and since it can't even be taken on its own - do you have reasons to think it's likely to be that big a win for any of these already huge Big Pharma companies?", "score": 2, "replies": [{"body": "So, keytruda is currently merckâ€˜s cash cow. Its patent is also running out. Anktiva has been shown to improve efficacy & lower side effects as an adjuvant to keytruda. If they had anktiva, they could extend keytrudaâ€˜s patents on that basis. Their own trials in this direction have all recently failed. They are an obvious candidate, but immunitybio has secured a deal with the serum institute of India and is filing for phase 3 for non small cell lung cancer as per news today. So either theyâ€™re pressuring or they are going it alone. Hope that is interesting context to you.", "score": 5, "replies": [{"body": "This is indeed very interesting, thanks for sharing it. This information suggests to me that ImmunityBio is trying to resist being bought out by Big Pharma, and instead wants to use deals to make profit on its own, growing its own share price independently.", "score": 1, "replies": [{"body": "Well yes, I think so too, but if not this is also what they would be doing if they donâ€™t intend to sell for lowball prices. So itâ€™s hard to tell imho. And np, I hope good things for this company. I think the drug is interesting, but biotech is so volatile.", "score": 2, "replies": []}]}]}, {"body": "Looks like you are not familiar with bio business.Read about the big pharma business operations, acquisitions and drug trials process etc.  before starting to investin biotech.", "score": 1, "replies": [{"body": "u/bamadesi\n\nI'm not sure where you're trying to go with your comment, but I'll just say the following:\n\n1). If by \"bio business\" you mean biotechs as a whole, well nobody is ever going to be familiar with all of them, and each biotech has its own idiosyncracies and unique selling points. Therefore, we ALL need to read about \"bio business.\" Also, as far as getting familiar is concerned, asking questions here is actually part of getting familiar with the sector and learning more about it. Nobody has a monopoly on knowledge.\n\n2) Big Pharma and biotechs are not the same thing. A financial win for a Biotech company may barely move the financial needle for a Big Pharma company that's worth multiples of billions, depending on the amount of sales of the drug. If a biotech's drug is not the only drug on the market for a given illness, the money made from that drug's market share will be limited, since the Total Addressable Market will be shared with the competing drugs. There are also drugs that most of the public who need them will never see, due to the unfortunate fact that those drugs are too expensive to be mass-produced for the wider market.\n\n3) A company's revenue is very different from its stock price action. Even when a drug is sold to the public, it isn't guaranteed to translate to significant stock price increase. If a biotech's stock price doesn't move much, then that biotech isn't attractive to private investors, even if it remains desirable for a big pharma company to invest in it.", "score": 2, "replies": []}]}]}]}]}]}, {"body": "[https://finance.yahoo.com/news/immunitybio-presents-positive-long-term-123000487.html](https://finance.yahoo.com/news/immunitybio-presents-positive-long-term-123000487.html)", "score": 1, "replies": []}]}, {"body": "If you just bought XBI, smaller biotech, at 65 and sold at 90â€¦ youâ€™d be up 700% in the last decade. Thatâ€™s yummy bio trading.", "score": 1, "replies": []}, {"body": "what are ur positions?", "score": 1, "replies": []}, {"body": "Doc Soon owns part of the Lakers? \n\nYou son of a bitch! I'm fucking in!", "score": 1, "replies": [{"body": "Yup, Patrick", "score": 2, "replies": [{"body": "bought in 207 shares", "score": 1, "replies": []}]}]}, {"body": "Well done.  Any updates?  I Own shares.", "score": 1, "replies": []}, {"body": "I believe the launch going well", "score": 1, "replies": []}]}
{"title": "Muskâ€™s xAI Has Discussed Deal for Share in Future Tesla Revenue â€”Â WSJ", "selftext": "", "id": "1fbwmae", "created_utc": 1725798524.0, "score": 0, "upvote_ratio": 0.39, "num_comments": 52, "comments": [{"body": "You do realize this has been debunked since last night and you are posting the article as breaking news?", "score": 19, "replies": [{"body": "If you have a debunking, I'd be interested to see it. \n\nI'm not seeing anything on the subreddit, and just came across this story now.", "score": -11, "replies": [{"body": "\"Tesla has learned a lot from discussions with engineers at xAI that have helped accelerate achieving unsupervised FSD, but there is no need to license anything from xAI.\" - [Musk.](https://x.com/elonmusk/status/1832618127189774374)", "score": 21, "replies": [{"body": "If there's no need to license anything from xAI, why was he pushing for a $5 billion Tesla investment in xAI back in July?", "score": 4, "replies": [{"body": "Investing in a company isn't reliant on needing to licence something they produce.", "score": 2, "replies": [{"body": "Generally there's some benefit to the investing company.", "score": 2, "replies": [{"body": "equity and collaboration of staff.", "score": 1, "replies": [{"body": "Yes, that's the benefit to Musk. What's the benefit to Tesla?", "score": 1, "replies": [{"body": "Collaboration on engineering projects helps Tesla. If the value of XAI increases, it helps Tesla.", "score": 1, "replies": [{"body": "If the projects being done at xAI would be helpful for Tesla, there is no good reason for them to be done outside of Tesla by Musk except to line Musk's pockets at Tesla's expense.", "score": 1, "replies": [{"body": "Yeah, well, you know, that's just like, uh, your opinion, man. There would be plenty of crossover between the AI needed for Optimus and a Generalised AI.", "score": 1, "replies": [{"body": "So why isn't it being done at Tesla?\n\nOutside of lining Musk's pocket, I mean.", "score": 1, "replies": [{"body": "Why does Tesla have to do everything? They should build the Roadster first. If you don't like how Musk does business, you should probably invest elsewhere.", "score": 1, "replies": [{"body": ">Why does Tesla have to do everything?\n\nWhy are Tesla's resources being used to benefit Musk rather than Tesla?", "score": 1, "replies": []}]}]}]}]}]}]}]}]}]}]}, {"body": "I'm hardly the arbiter of truth here, but given Musk's record on debunking news reports (ie, NV91), and his previous appeal to the Tesla board to invest $5Bn in xAI, I'm hesitant to call new denials on his part the unassailable word on the topic.", "score": -9, "replies": [{"body": "Asks for source, gets a rebuttal from Musk, says it doesn't count. lol\n\nWhat would be a good source for you then?", "score": 7, "replies": [{"body": "At this point I would only accept a written letter from Tesla's board, signed by the directors and filed with the SEC, as reliable. \n\nPeople are downvoting Recoil42, but on the facts he is correct.  Musk has lied a lot in the recent past.  For me, he's lied enough that his word is essentially worthless to me now.  Examples:\n\n* Mr. Musk stated in April 2022 that he was done selling Tesla stock, and then proceeded to dump Billions more onto the open market through December of that year.  See timeline here: [https://www.investopedia.com/musk-halt-selling-2022-7069052](https://www.investopedia.com/musk-halt-selling-2022-7069052)\n* Mr. Musk called the Reuters article on the cancelled NV91 project (manually driven NGV) false, but my review of Tesla's reports and SEC filings show that the Reuters report is actually true.  The manually driven NGV, originally based on the Gen3 platform, was abruptly scrapped and replaced by a Gen2.5 product, which uses elements of the current Model 3/Y and some upgrades from the Gen3 platform.  \n* Mr. Musk has repeatedly spread lies about people, including Paul Pelosi, Ben Brody (22 year old college student [wrongly accused of participating in a riot](https://www.usatoday.com/story/news/investigations/2023/10/06/ben-brody-elon-musk-lawsuit/71079585007/)), and Yoel Roth (former Twitter executive that Musk [wrongly accused](https://www.yahoo.com/news/elon-musk-tried-intimidate-silence-213651421.html) of promoting pedophilia in an academic paper)", "score": 6, "replies": [{"body": "So when Musk said he done done selling, was that supposed to mean forever? I, and most people, assumed it meant in that time period.\n\nThe Reuters article said they were scrapping a cheaper car in favor of the Robotaxi. They were cancelling NV91 and moving to a Gen 2.5. The headline of them no longer making a manually driven cheaper car was false even though yes they cancelled NV91.\n\nMusk can be annoying when he denies things explicitly even though there's a grain of truth to it but none of these examples are of him straight up lying about his businesses.", "score": -1, "replies": [{"body": ">So when Musk said he done done selling, was that supposed to mean forever? I, and most people, assumed it meant in that time period.\n\nI assumed he meant he was done selling in April 2022 for the purposes of buying Twitter, given the context of that transaction and what was going on around it.  Obviously that was a lie, given that Musk continued to dump Billions in stock even after the transaction had closed.  His actions speak for themselves.\n\n \n\n>The headline of them no longer making a manually driven cheaper car was false even though yes they cancelled NV91.\n\nHere's the problem I have:\n\nTesla specifically promised investors at Investor Day 2023 that they would develop and ship a next-generation platform vehicle.\n\n* Slide 47 of the presentation specifies 40% reduction in production line footprint and 50% reduction in costs.\n   * This is the product that Reuters was discussing: [https://archive.is/AjP92](https://archive.is/AjP92) - \"Tesla has canceled the long-promised inexpensive car **that investors have been counting on**\"\n\n  \nGen2.5 is realistically unlikely to achieve those same cost savings.  Tesla even says this in its filings: [https://www.sec.gov/Archives/edgar/data/1318605/000095017024046895/tsla-ex99\\_1.htm](https://www.sec.gov/Archives/edgar/data/1318605/000095017024046895/tsla-ex99_1.htm)\n\nPage 10 of the slide deck says;\n\n*\"This update may result in achieving less cost reduction than previously expected but enables us to prudently grow our vehicle volumes in a more capex efficient manner during uncertain times. This would help us fully utilize our current expected maximum capacity of close to three million vehicles, enabling more than 50% growth over 2023 production before investing in new manufacturing lines.* \n\n*Our purpose-built robotaxi product will continue to pursue a revolutionary â€œunboxedâ€ manufacturing strategy.\"*\n\n  \nPeople can dance around this all they want, but the **fact** of the matter is that Tesla promised investors something in 2023, that they then canceled.  Musk pulled a \"bait and switch\" here: killing NV91 and then lying about the Reuters article being false on the grounds that Tesla would build a Gen2.5 car on the 3/Y platform (which was NOT what was promised at Investor Day 2023). \n\n  \nI've been a TSLA shareholder since 2011.  The outright dishonesty of Mr. Musk in recent years stands in stark contrast to how he was a decade ago.", "score": 4, "replies": [{"body": "â€œNo further TSLA sales planned after todayâ€ \n\nOrâ€¦.he sold what he thought was enough, wasnâ€™t able to raise the amount of money he needed, and had to sell more to complete the purchase. Something not *planned* in April 2022.", "score": 0, "replies": []}]}, {"body": "Musk didnâ€™t even say he is done selling. He said, â€œNo further TSLA sales planned after today.â€ Keyword there is planned. 4 months later he sold again.", "score": 1, "replies": []}]}, {"body": "You have to quote the actual tweet, \n\nâ€œNo further TSLA sales planned after todayâ€ \n\nThat does not say â€œI am done sellingâ€. It means exactly what he said, no further sales planned as of April 2022. He sold again 4 months later in August. Believe it or not but people can make new plans to do things in 4 months. This isnâ€™t a lie, and you shouldnâ€™t be claiming it is.", "score": -2, "replies": [{"body": "It defies common sense to claim that (1) \"no further sales planned\" and (2) \"I am done selling\" aren't basically the same thing. \n\n\n\n>Believe it or not but people can make new plans to do things in a 4 months.\n\nIf I tell my wife that I'll pick up the weekly food shopping next Friday, but then \"make new plans\" to drink beer and play poker with my friends instead, then I lied.  \n\n  \nYour arguments make no sense and are basically gaslighting.", "score": 3, "replies": [{"body": "Nonsense. Regular people can completely change their minds on what they're doing in a span of 4 months. Musk is crazier than most people and probably has a billion ideas for what he could do with the money if he sold. You can't tell me with a straight face that Musk couldn't possibly have changed plans in a span of 4 months.\n\nYour analogy is poor, let me fix it for you. Told wife you'll buy the groceries every week. You do this for 4 months then decide you don't wanna do it anymore. Simple.", "score": -2, "replies": [{"body": "You miss the point. \n\nWhether or not you want to change your plans, is different from whether or not you keep your word.", "score": 5, "replies": [{"body": "What word? Please tell me where in the tweet it says he will never sell ever again? Read it again, slowly, it says no sales PLANNED after today.", "score": -1, "replies": [{"body": "Again, in the context of his communications and what was going on with Twitter, I (and many others) interpreted Mr. Musk to mean that he would not sell any more TSLA stock to fund his purchase of Twitter.\n\n* You can ignore the context all you want, but it's there.  Mr. Musk's statement cannot be reasonably interpreted in a vacuum. \n\n\n\nNobody in the OG TSLA shareholder community (mostly IPO-2012 investors at Tesla Motors Club forums) expected Mr. Musk to hold his stock forever. \n\nIn fact, Mr. Musk tweeted in 2018 that he intended to sell approximately 2 decades later in **2038**, to fund Mars colonization: [https://electrek.co/2018/06/15/elon-musk-plan-sell-major-stake-tesla-finance-spacex-mars-plans/](https://electrek.co/2018/06/15/elon-musk-plan-sell-major-stake-tesla-finance-spacex-mars-plans/)\n\n>Major disbursements in about 20 years when Tesla is steady state.\n\nSource: [https://twitter.com/elonmusk/status/1007663283648647169?ref\\_src=twsrc%5Etfw](https://twitter.com/elonmusk/status/1007663283648647169?ref_src=twsrc%5Etfw) (June 15, 2018)", "score": 2, "replies": [{"body": "Are you going to ignore what I said previously? Musk tried to raise money to purchase Twitter, he was able to raise some of it, not all of it. Itâ€™s extremely likely other investors bailed out, requiring more money from him, requiring him to sell more tsla shares.", "score": 0, "replies": []}]}]}]}]}]}]}]}, {"body": ">What would be a good source for you then?\n\nSomeone who hasn't demonstrated themselves untrustworthy on 'debunking' things, probably. Again, see NV91.", "score": 3, "replies": [{"body": "Trump didn't deny the reports, he said they were ''innacurate\". Just like he said he wasn't giving Trump $45 million a month because he was funnelling the money through a SuperPAC.", "score": 1, "replies": []}, {"body": "Tesla should be flexing its Agile corporate ability right now and go full speed into Autonomy. Once regulatory approval for FSD, a Mass market car can still be on the table. It  just makes Little sense for them to do that right now since their mid teir cars currentnly are either at the top or among the best selling affordible cars. \n \nWhy osbourne themselves when they are dominating with pricier versions?", "score": 0, "replies": []}, {"body": "\"Tesla scraps low-cost car plans amid fierce Chinese EV competition\"\n\nTesla scrapped NV91 and media ran with the headline saying they weren't making a cheaper car and only doing Robotaxi. Yes they cancelled NV91 but they're still making a cheaper car. Both things could be true when Musk said they're still making a cheaper car.", "score": -1, "replies": [{"body": ">Yes they cancelled NV91 but they're still making a cheaper car.\n\nSo we agree Tesla scrapped their low-cost car plans.", "score": 4, "replies": []}]}]}]}]}]}, {"body": "Sorry for the confusion. There actually was another post... I removed the prior post as the title was editorialized such that the submission title was the exact opposite of the article's title.", "score": 0, "replies": []}]}]}, {"body": "Just like Muskâ€™s discussions at OpenAI, Tesla will be the cash cow that funds the xAI. \nNot good", "score": 7, "replies": []}, {"body": "If Musk wants to argue that xAI isn't a Tesla competitor and is a completely separate thing then that's fine.\n\nIf Tesla uses any part of xAI's software in the car in any capacity then it's clearly a competitor and there's massive conflict of interest issues.", "score": 9, "replies": [{"body": "I think a smarter move for them would be to make the FSD interaction API public and then announce a partnership with xAI to integrate VLM. This would avoid any suspicion while still fulfilling Musk's demands.", "score": 1, "replies": []}, {"body": "I believe he used tesla funds to buy the nvda Ai hardware.", "score": -11, "replies": [{"body": "You believe wrong and ought to check before spreading wrong stuff", "score": 7, "replies": []}, {"body": "both Tesla and Twitter made 2 huge orders of nvda hardware\n\nAustin TX is building out a huge datacenter whileTwitter was ready to receive cards.\n\nThey reversed delivery of the orders, so Twitter got Austin's order and Austin would get Twitter's order a little later.\n\nBecause Austin wouldn't be ready to receive/install the cards for a few months\n\nThis way all the cards get used as soon as they are delivered instead of sitting in a room.", "score": 5, "replies": [{"body": "xAI and Twitter are not same company. Twitter only owns part of xAI as exchange for sharing their data with xAI.", "score": 5, "replies": [{"body": "You're right, I over-simplified the story in my head. Both X and xAI each got some cards from the swap with Tesla's order.\n\n[https://www.cnbc.com/2024/06/04/elon-musk-told-nvidia-to-ship-ai-chips-reserved-for-tesla-to-x-xai.html](https://www.cnbc.com/2024/06/04/elon-musk-told-nvidia-to-ship-ai-chips-reserved-for-tesla-to-x-xai.html)", "score": 2, "replies": []}]}, {"body": "Yes, we know what story Elon used to attempted to save face. What's the truth though?", "score": 2, "replies": []}, {"body": "As it would have been much harder to use the other checkbook. And more expensive, and illegal and a liability to tesla shareholders.", "score": 2, "replies": []}]}, {"body": "\"The plaintiffs also point to cnbc's reporting that Musk diverted a sizable shipment of AI processors from Nvidia that had been on reserved for Tesla to his social media company X, claiming that Tesla's new data center in Texas was still under construction and didn't have room to store them.\" This is one of several shareholders suits Tesla is now fighting.", "score": 1, "replies": []}]}]}, {"body": ">Under a proposed arrangement as described to investors, Tesla would license xAIâ€™s AI models to help power its driver-assistance software, called Full Self-Driving, and share some of that revenue with the startup, according to people familiar with the matter. xAI would assist in developing other features for Tesla, including a Siri-like voice assistant inside its electric cars and software to power its humanoid robot Optimus, the people said.\n\n>  \nFormalizing a partnership with xAI in which Tesla would hand over some of its revenue and future AI development to a separate Musk-controlled company would add to the tech mogulâ€™sÂ [practice of sharing assets](https://www.wsj.com/articles/elon-musks-new-boring-co-faced-questions-over-spacex-financial-ties-11545078371?mod=article_inline)Â freely across his business empire.", "score": 1, "replies": [{"body": "He probably already had those things . He is just double charging tesla investors and lieing after the fact. Full disclosure I no longer have any interest in tesla. I  divested when Elon endorced( conspired with) Trump.", "score": 1, "replies": []}]}, {"body": "Shouldnâ€™t it be the other way around? TSLA gets 50% of xAI revenue for xAI using its software?", "score": 1, "replies": []}]}
{"title": "STOCKS TO HOLD FOR 5 TO 10 YEARS", "selftext": "Hi everyone.\n\nLast July I have started to buy some shares from WMT and KO.\n\nThe plan is to grow the portfolio with 5 to 10 companies and hold for 5 to 10 years and increase every month with premium received sellings puts plus some savings.\n\nI've been moving the money from my margin acc to the cash one where I keep the position.\n\nI've been looking to buy others companies but I would like to know if you guys can give some suggestions.\n\nAt the moment I am thinking about T, AMZN GE.\n\nThanks in advance.", "id": "1fc1fuk", "created_utc": 1725811891.0, "score": 0, "upvote_ratio": 0.27, "num_comments": 27, "comments": [{"body": "Wrong sub. You probably want /r/ValueInvesting", "score": 27, "replies": [{"body": "Sorry. I didn't know about the one you mentioned.\n\nBut as I am selling puts I was thinking it is part of the process what to do with the money you collect with the premium.\n\nI am going to check the one you mentioned.\n\nThanks", "score": 2, "replies": [{"body": "Selling puts as a means of picking up shares for long term holding is a legit and useful strategy. Youâ€™re effectively buying them at a discount.\n\nYou can also sell calls to get rid of shares and are effectively selling them at a higher price", "score": 4, "replies": []}]}]}, {"body": "I have read of people doing this.\n\nSelling puts and when assigned just selling calls to add more income.\n\nSo they hold shares, sell puts and covered calls. Plus collect the dividends.", "score": 5, "replies": [{"body": "Also known as The Wheelâ„¢", "score": 18, "replies": []}]}, {"body": "This sub doesnt intend to hold shares long term...", "score": 6, "replies": [{"body": "Why? I thought it's about making money on theta? You are either holding shares, or trying to buy them...", "score": 1, "replies": [{"body": "You don't necessarily need hold the shares. Eg. cash-secured puts\n\nSome people prefer this method to avoid the loss exposure from holding a stock", "score": 1, "replies": []}]}]}, {"body": "SPY. Make it easy", "score": 5, "replies": [{"body": "I was thinking about SPY long term. Thanks", "score": 3, "replies": []}]}, {"body": "I would say look at the energy sector.  SMR's and solar stocks. Once the $NVDA fan boys realize energy is the choke point for future growth and AI there will be floods of money into this sector.  I don't want to give away the specific stocks as I need more time to wheel these stocks and accumulate more, but there are some big life changing opportunities in the energy sector.", "score": 4, "replies": []}, {"body": "While I don't know shit about T, AMZN is a solid choice, and you misspelled GME ðŸ˜˜", "score": 8, "replies": [{"body": "I am not a cat!", "score": 3, "replies": []}]}, {"body": "I wouldn't buy any companies for the next two months, then buy blue chips around December or so when they are done bottoming out.", "score": 2, "replies": [{"body": "You think things will dump a lot in q4?", "score": 1, "replies": [{"body": "I personally can't predict the future but alot of people can on reddit and they said it will.", "score": 1, "replies": []}]}]}, {"body": "MAYBE TRY WMT MSFT JPM", "score": 2, "replies": []}, {"body": "There are tons of quality stocks to choose from.  Here are a few. \n\nVisa \nAmex\nWalmart\nMeta\nNvidia\nCostco\nExpedia\nDisney \nMcDonaldâ€™s\nUber\nAdobe \n\n.", "score": 2, "replies": []}, {"body": "NVDA\n\nAAPL\n\nNVDL", "score": 2, "replies": []}, {"body": "This is r/thetagang, we only sell options to r/wallstreetbets :-)\n\nr/stock or r/valueinvesting are probably more appropriate for your question", "score": 1, "replies": []}, {"body": "Be sure to understand that option volume on some of the blue chips is low. \n\nI'd also recommend researching examples of value traps.", "score": 1, "replies": []}, {"body": "PFE", "score": 1, "replies": []}, {"body": "I think PLTR should great for the long term", "score": 0, "replies": []}, {"body": "VT, or if youâ€™re adventurous VTI and VXUS", "score": 0, "replies": []}, {"body": "ASTS", "score": 0, "replies": []}, {"body": "TQQQ", "score": 0, "replies": []}, {"body": "PLTR", "score": -1, "replies": []}]}
